Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover	0.00 -
cash per share	1.39 -	2.51 79.99%	12.04 380.25%	7.96 33.87%	8.27 3.92%	7.38 10.77%
company equity multiplier	1.66 -	1.34 19.22%	1.10 17.99%	1.25 13.72%	1.24 0.35%	1.29 3.44%
days of inventory outstanding
days of payables outstanding						3.92K -
days of sales outstanding	23.91K -
dividend yield
ebit per revenue	-1.70K -
ebt per ebit	0.99 -	0.99 0.47%	0.99 0.46%	0.76 23.57%	0.97 28.12%	1.09 11.99%
effective tax rate	-0.00 -	-0.00 89.49%	-0.00 1,061.98%	0.00 148.01%	0.00 17.42%	0.00 2.42%
enterprise value multiple	-16.59 -	-14.57 12.18%	-11.78 19.17%	-13.31 13.01%	-4.57 65.65%	-3.99 12.65%
fixed asset turnover	0.05 -
free cash flow per share	-1.36 -	-1.20 11.37%	-3.12 159.31%	-3.75 20.46%	-3.15 16.16%	-3.19 1.27%
gross profit margin	1 -
interest coverage					-88.27 -
inventory turnover
long term debt to capitalization			0.00 -	0.11 3,214.78%	0.09 13.30%	0.09 4.71%
net income per ebt	0.90 -	1.00 11.24%	1.00 0.34%	1.00 0.55%	1.00 0.03%	1.06 5.75%
net profit margin	-1.50K -
operating cash flow per share	-1.34 -	-1.19 11.34%	-3.09 159.38%	-3.61 16.88%	-3.10 14.18%	-3.18 2.56%
operating profit margin	-1.70K -
payables turnover						0.09 -
pretax profit margin	-1.67K -
price fair value	16.91 -	9.93 41.27%	4.38 55.91%	9.85 124.77%	2.45 75.09%	2.27 7.61%
receivables turnover	0.02 -
return on assets	-0.51 -	-0.45 12.08%	-0.32 28.22%	-0.36 11.44%	-0.41 13.30%	-0.52 26.97%
return on capital employed	-0.68 -	-0.53 21.92%	-0.35 33.96%	-0.53 49.61%	-0.47 10.72%	-0.52 9.46%
return on equity	-0.85 -	-0.60 28.98%	-0.36 41.13%	-0.45 26.74%	-0.51 12.90%	-0.67 31.33%
total debt to capitalization		0.01 -	0.01 40.81%	0.11 1,776.91%	0.09 15.75%	0.09 0.53%

NASDAQ:ZNTL

Zentalis Pharmaceuticals, Inc.

Last Close

11.96

17/05 20:00

Market Cap

897.31M

Beta: 1.83

Volume Today

493.17K

Avg: 602.77K

PE Ratio

−2.91

PFCF: −3.94